2,188
Views
3
CrossRef citations to date
0
Altmetric
Review

Transcatheter aortic valve replacement: clinical safety and performance data

, , &
Pages 899-911 | Received 08 Apr 2019, Accepted 26 Sep 2019, Published online: 04 Oct 2019

References

  • Harken DESH, Taylor WF, Lefimine AA. Partial and complete prosthese in aortic insufficiency. J Thorac Cardiovasc Surg. 1960;40:744–762.
  • Varadarajan P, Kapoor N, Bansal RC, et al. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: results from a cohort of 277 patients aged≥ 80 years. Eur J Cardiothorac Surg. 2006;30(5):722–727.
  • Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease. Eur Heart J. 2003;24(13):1231–1243.
  • Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes. 2009;2(6):533–539.
  • Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006–3008.
  • Puri R, Chamandi C, Rodriguez-Gabella T, et al. Future of transcatheter aortic valve implantation—evolving clinical indications. Nat Rev Cardiol. 2018;15:57–65.
  • Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium. Eur Heart J. 2010;32(2):205–217.
  • Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. Eur Heart J. 2012;33(19):2403–2418.
  • RIVM. Overview of CE marked TAVR. 2018. [cited 2017 Jun]. Available from: http://www.rivm.nl/Onderwerpen/M/Medische_hulpmiddelen/Hartkleppen/Overview_of_transcatheter_heart_valve_systems_CE_marked_and_in_Clinical_Investigations
  • Gupta SD, Das S, Ghose T, et al. Controlled transient respiratory arrest along with rapid right ventricular pacing for improving balloon stability during balloon valvuloplasty in pediatric patients with congenital aortic stenosis-A retrospective case series analysis. Ann Card Anaesth. 2010;13(3):236.
  • Brennan PF, Spence M. Self-expanding CENTERA valve for the treatment of severe, symptomatic aortic stenosis. Future Cardiol. 2019;15(2):79–84.
  • Choudhury T, Solomonica A, Bagur R. The Evolut R and Evolut PRO transcatheter aortic valve systems. Expert Rev Med Devices. 2019;16(1):3–9.
  • Solomonica A, Choudhury T, Bagur R. Newer-generation of Edwards transcatheter aortic valve systems: SAPIEN 3, Centera, and SAPIEN 3 ultra. Expert Rev Med Devices. 2019;16(2):81–87.
  • Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv. 2018;11(2):160–168.
  • Reichenspurner H, Schaefer A, Schäfer U, et al. Self-expanding transcatheter aortic valve system for symptomatic high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2017;70(25):3127–3136.
  • Athappan G, Gajulapalli RD, Tuzcu ME, et al. A systematic review on the safety of second-generation transcatheter aortic valves. EuroIntervention. 2016;11(9):1034–1043.
  • del Val D, Ferreira-Neto AN, Asmarats L, et al. Transcatheter aortic valve replacement: relative safety and efficacy of the procedure with different devices. Expert Rev Med Devices. 2019;16(1):11–24.
  • Wenaweser P, Stortecky S, Schutz T, et al. Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. EuroIntervention. 2016;12(1):71–77.
  • Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention. 2008;4(2):242–249.
  • Bijuklic K, Tuebler T, Reichenspurner H, et al. Midterm stability and hemodynamic performance of a transfemorally implantable nonmetallic, retrievable, and repositionable aortic valve in patients with severe aortic stenosis. Up to 2-year follow-up of the direct-flow medical valve: a pilot study. Circ Cardiovasc Interventions. 2011;4(6):595–601.
  • Zhang S, Kolominsky-Rabas PL. How TAVI registries report clinical outcomes—A systematic review of endpoints based on VARC-2 definitions. PLoS One. 2017;12(9):e0180815.
  • Gatto L, Biondi-Zoccai G, Romagnoli E, et al. New-generation devices for transcatheter aortic valve implantation. Minerva Cardioangiol. 2018;66(6):747–761.
  • Gomes B, Geis NA, Chorianopoulos E, et al. Improvements of procedural results with a new‐generation self‐expanding transfemoral aortic valve prosthesis in comparison to the old‐generation device. J Interv Cardiol. 2017;30(1):72–78.
  • Wiegerinck EM, Van Kesteren F, Van Mourik MS, et al. An up-to-date overview of the most recent transcatheter implantable aortic valve prostheses. Expert Rev Med Devices. 2016;13(1):31–45.
  • Herrmann HC, Thourani VH, Kodali SK, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–140.
  • Bapat V, Frank D, Cocchieri R, et al. Transcatheter aortic valve replacement using transaortic access: experience from the multicenter, multinational, prospective ROUTE registry. JACC Cardiovasc Interv. 2016;9(17):1815–1822.
  • Wassef AW, Rodes-Cabau J, Liu Y, et al. The learning curve and annual procedure volume standards for optimum outcomes of transcatheter aortic valve replacement: findings from an international registry. JACC Cardiovasc Interv. 2018;11(17):1669–1679.
  • Regulation (EU). 2017/745 of the European Parliament and of the council of 5 April 2017 on medical devices, amending directive 2001/83/EC, regulation (EC) No 178/2002 and regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC.
  • Tarantini G, Nai Fovino L, Gersh BJ. Transcatheter aortic valve implantation in lower-risk patients: what is the perspective? Eur Heart J. 2018;39:658–666.
  • Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of structural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation. 2018;137(4):388–399.
  • Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017;52(3):408–417.
  • Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol. 2019;73(5):546–553.
  • Eltchaninoff H, Durand E, Avinee G, et al. Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. EuroIntervention. 2018;14(3):e264–e271.
  • Holy EW, Kebernik J, Abdelghani M, et al. Long-term durability and haemodynamic performance of a self-expanding transcatheter heart valve beyond five years after implantation: a prospective observational study applying the standardised definitions of structural deterioration and valve failure. EuroIntervention. 2018;14(4):e390–e396.
  • Panico R, Giannini C, De MC, et al. Long-term results and durability of the CoreValve transcatheter aortic bioprosthesis: outcomes beyond five years. EuroIntervention. 2019;14(16):1639–1647.
  • Barbanti M, Tamburino C. Late degeneration of transcatheter aortic valves: pathogenesis and management. EuroIntervention. 2016;12(Y):Y33–6.
  • Durko AP, Osnabrugge RL, Kappetein AP. Long-term outlook for transcatheter aortic valve replacement. Trends Cardiovasc Med. 2018;28:174–183.
  • Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. NEJM. 2019;380(18):1706–1715.
  • Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. NEJM. 2019;380(18):1695–1705.
  • Terré JA, George I, Smith CR. Pros and cons of transcatheter aortic valve implantation (TAVI). Ann Cardiothorac Surg. 2017;6(5):444–452.
  • Petronio AS, Capranzano P, Barbato E, et al. Current status of transcatheter valve therapy in Europe: results from an EAPCI survey. EuroIntervention. 2016;12(7):890–895.